Skip to main content

News & Announcements

Awards, appointments, new team members, and breakthroughs from across the TIME Lab consortium.

April 2026

TIME Lab — Join Our Team

Opportunities to join the TIME Lab!

The Pillarisetty Lab in the UW TIME lab is actively seeking graduate students from the University of Washington/Fred Hutch joint program in Molecular and Cellular Biology. Our labs offer a highly collaborative, multidisciplinary, and collegial training environment with access to unique human tumor tissue platforms and cutting-edge imaging technologies.

We are always interested in hearing from exceptional postdoctoral candidates and medical trainees seeking advanced research training. We are particularly interested in candidates with backgrounds in tumor immunology, spatial biology, single-cell genomics, or translational cancer research.

To express interest or learn more about available positions, please contact Dr. Pillarisetty directly.

March 2026

New Principal Investigator in the TIME Lab!

Congratulations to Dr. Sheela Damle on her recent appointment as Associate Professor at Fred Hutch Cancer Center who just started her in her new role this March! Sheela will continue her groundbreaking work as physician scientist in the TIME lab where she also conducted her reseach training under the mentorship of Dr. Venu Pillarisetty

December 2025

KL2 award announcement

New Funding Alert!

Congratulations to Dr. Sheela Damle who recently was awarded a prestigious KL2 Multidisciplinary Clinical Research Career Development Program Award from the National Institutes of Health and the University of Washington's Institute of Translational Health Sciences (ITHS) CTSA to support her training as a physician scientist!

Learn More

November 2025

New postdoc announcement

New Publication in Gastroenterology!

Congratulations to Dr. Jason Carter and colleagues in the TIME and Pillarisetty labs on the recent publication of their Fibolamellar Cancer (FLC) research. Published in Gastroenterology"Overcoming CXCR4-Mediated T-Cell Exclusion Potentiates Antitumor Cytotoxicity in Fibrolamellar Carcinoma" they demonstrate that combination PD-1 and CXCR4 inhibition can cooperatively overcome immune resistance in Fibrolamellar Cancer tumors!

New Publication!